Nicholette D Palmer Allred1,2, Laura M Raffield2,3, Joycelyn C Hardy4, Fang-Chi Hsu5, Jasmin Divers5, Jianzhao Xu2, S Carrie Smith6, Christina E Hugenschmidt7, Benjamin C Wagner8, Christopher T Whitlow8, Kaycee M Sink7, Joseph A Maldjian8, Jeff D Williamson7, Donald W Bowden6,2, Barry I Freedman9. 1. Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC nallred@wakehealth.edu. 2. Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC. 3. Molecular Genetics and Genomics Program, Wake Forest School of Medicine, Winston-Salem, NC. 4. Department of Biological Sciences, Clemson University, Clemson, SC. 5. Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC. 6. Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC. 7. Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC. 8. Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC. 9. Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC.
Abstract
OBJECTIVE: Dementia is a debilitating illness with a disproportionate burden in patients with type 2 diabetes (T2D). Among the contributors, genetic variation at the apolipoprotein E locus (APOE) is posited to convey a strong effect. This study compared and contrasted the association of APOE with cognitive performance and cerebral structure in the setting of T2D. RESEARCH DESIGN AND METHODS: European Americans from the Diabetes Heart Study (DHS) MIND (n = 754) and African Americans from the African American (AA)-DHS MIND (n = 517) were examined. The cognitive battery assessed executive function, memory, and global cognition, and brain MRI was performed. RESULTS: In European Americans and African Americans, the APOE E4 risk haplotype group was associated with poorer performance on the modified Mini-Mental Status Examination (P < 0.017), a measure of global cognition. In contrast to the literature, the APOE E2 haplotype group, which was overrepresented in these participants with T2D, was associated with poorer Rey Auditory Verbal Learning Test performance (P < 0.032). Nominal associations between APOE haplotype groups and MRI-determined cerebral structure were observed. CONCLUSIONS: Compared with APOE E3 carriers, E2 and E4 carriers performed worse in the cognitive domains of memory and global cognition. Identification of genetic contributors remains critical to understanding new pathways to prevent and treat dementia in the setting of T2D.
OBJECTIVE:Dementia is a debilitating illness with a disproportionate burden in patients with type 2 diabetes (T2D). Among the contributors, genetic variation at the apolipoprotein E locus (APOE) is posited to convey a strong effect. This study compared and contrasted the association of APOE with cognitive performance and cerebral structure in the setting of T2D. RESEARCH DESIGN AND METHODS: European Americans from the Diabetes Heart Study (DHS) MIND (n = 754) and African Americans from the African American (AA)-DHS MIND (n = 517) were examined. The cognitive battery assessed executive function, memory, and global cognition, and brain MRI was performed. RESULTS: In European Americans and African Americans, the APOE E4 risk haplotype group was associated with poorer performance on the modified Mini-Mental Status Examination (P < 0.017), a measure of global cognition. In contrast to the literature, the APOE E2 haplotype group, which was overrepresented in these participants with T2D, was associated with poorer Rey Auditory Verbal Learning Test performance (P < 0.032). Nominal associations between APOE haplotype groups and MRI-determined cerebral structure were observed. CONCLUSIONS: Compared with APOE E3 carriers, E2 and E4 carriers performed worse in the cognitive domains of memory and global cognition. Identification of genetic contributors remains critical to understanding new pathways to prevent and treat dementia in the setting of T2D.
Authors: Virginia G Wadley; Frederick W Unverzagt; Lisa C McGuire; Claudia S Moy; Rodney Go; Brett Kissela; Leslie A McClure; Michael Crowe; Virginia J Howard; George Howard Journal: Ann Neurol Date: 2011-05-26 Impact factor: 10.422
Authors: Jesus J Gomar; Maria T Bobes-Bascaran; Concepcion Conejero-Goldberg; Peter Davies; Terry E Goldberg Journal: Arch Gen Psychiatry Date: 2011-09
Authors: K H Buetow; M Edmonson; R MacDonald; R Clifford; P Yip; J Kelley; D P Little; R Strausberg; H Koester; C R Cantor; A Braun Journal: Proc Natl Acad Sci U S A Date: 2001-01-02 Impact factor: 11.205
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Fang-Chi Hsu; Kaycee M Sink; Christina E Hugenschmidt; Jeff D Williamson; Timothy M Hughes; Nicholette D Palmer; Jianzhao Xu; S Carrie Smith; Benjamin C Wagner; Christopher T Whitlow; Donald W Bowden; Joseph A Maldjian; Jasmin Divers; Barry I Freedman Journal: J Gerontol A Biol Sci Med Sci Date: 2018-03-02 Impact factor: 6.053
Authors: Olga Lucia Pedraza; Isis Camacho; Fabio Alexander Sierra; Rubio-Gómez Cladelis; Ana Maria Salazar; Maria Camila Montalvo; Hector Daniel Morillo; Angela Lozano; Luz Dary Gutiérrez-Castañeda; Lilian Torres-Tobar; Cesar Piñeros Journal: Dement Neuropsychol Date: 2021 Oct-Dec
Authors: Mark A Espeland; Kathleen M Hayden; Samuel N Lockhart; Hussein N Yassine; Siobhan Hoscheidt; Sevil Yasar; Jose A Luchsinger; Rebecca H Neiberg; Roberta Diaz Brinton; Owen Carmichael Journal: J Gerontol A Biol Sci Med Sci Date: 2020-03-09 Impact factor: 6.053